Actively Recruiting
Long-Term Safety Follow-Up Study of Cellgram-LC Treatment in Patients with Alcoholic Liver Cirrhosis from the PMC-P-07 Trial
Led by Pharmicell Co., Ltd. · Updated on 2026-09-21
100
Participants Needed
14
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
This observational study focuses on patients with alcoholic liver cirrhosis who previously received Cellgram-LC treatment in the PMC-P-07 clinical trial. It aims to learn about the long-term safety of Cellgram-LC by monitoring key outcomes such as adverse events of special interest AESI and the occurrence of liver transplantation over five years following treatment. Participants who took part in the earlier PMC-P-07 study and received Cellgram-LC will be invited to join this follow-up study. The study involves annual telephone visits over a five-year period after the initial Cellgram-LC administration to collect information on any AESI or liver transplantation events. During the study, participants will be contacted by phone once a year to report health status related to AESI and liver transplantation. The research team will assess these outcomes annually to understand the long-term safety profile of Cellgram-LC. This follow-up period lasts five years from the date of Cellgram-LC administration, allowing close monitoring of participants health over time.
CONDITIONS
Brief Title
Long-Term Follow-up of Patients With Alcoholic Liver Cirrhosis Treated With Cellgram-LC
Research Team
Y
YUJEONG KIM
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here